Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.

Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance. Where Is Vertex Pharmaceuticals Standing Right Now?

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...

The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.

A single Journavx pill costs around $15 without insurance, according to Vertex Pharmaceuticals, the drug's manufacturer. Journavx's FDA approval was based on studies of patients right after surgery.

Vertex Pharmaceuticals Inc. (VRTX) Vertex Pharmaceuticals is a biopharmaceutical company that specializes in developing therapies to treat cystic fibrosis.

Sonoma Pharmaceuticals Inc is listed on the CBOE trading with ticker code SNOA.US. It has a market capitalisation of $5.88m, with approximately 1.64m shares in issue. Over the last year, Sonoma ...

Overview of Hepatitis C Drug MarketThe global Hepatitis C Drug Market is valued at USD 7.95 Billion in 2024 and is projected ...